scispace - formally typeset
J

Jonathan P. Caulkins

Researcher at Carnegie Mellon University

Publications -  366
Citations -  9671

Jonathan P. Caulkins is an academic researcher from Carnegie Mellon University. The author has contributed to research in topics: Drug control & Legalization. The author has an hindex of 51, co-authored 355 publications receiving 8701 citations. Previous affiliations of Jonathan P. Caulkins include Heinz College & Washington University in St. Louis.

Papers
More filters
Book

Optimal Control of Nonlinear Processes: With Applications in Drugs, Corruption, and Terror

TL;DR: In this article, the authors present a tour-d'horizon approach for infinite horizon systems, which is based on the extension of the maximum-principle (MP) principle.
Journal ArticleDOI

Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state.

TL;DR: In this paper, the authors assess trends and variation in the market share of product types and potency sold in a legal cannabis retail market, and estimate how potency and purchase quantity influence price variation for cannabis flower.
Journal ArticleDOI

What Price Data Tell Us about Drug Markets

TL;DR: In this article, empirical evidence on drug prices and their implications for understanding of drug markets and for policy are reviewed. But the most striking characteristics of drug prices are their high lev.....
Book

Drug Policy and the Public Good

TL;DR: Drug Policy and the Public Good as mentioned in this paper presents the accumulated scientific knowledge of direct relevance to the development of drug policy on local, national, and international levels, and explores the relationship between drug policy and public good.
Journal ArticleDOI

Drug policy and the public good: evidence for effective interventions

TL;DR: relevant evidence is reviewed and the likely effects of fuller implementation of existing interventions are outlined, which are capable of making drugs less available, reducing violence in drug markets, lessening misuse of legal pharmaceuticals, and reducing drug use and its consequences in established drug users.